RLAY Q4 2020 Earnings — Relay Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RLAYRelay Therapeutics, Inc.

$2B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$83M

Gross Profit

$82M98.9% margin

Operating Income

$35M42.3% margin

Net Income

$35M42.7% margin

EPS (Diluted)

$0.50

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$800M

Total Liabilities

$37M

Stockholders' Equity

$763M

Cash & Equivalents

$448M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$83M	$0	—
Gross Profit	$82M	$0	—
Operating Income	$35M	-$26M	+235.4%
Net Income	$35M	-$24M	+247.5%